This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

Expanded access is no longer available for this treatment.
Health Resources and Services Administration (HRSA)
Information provided by (Responsible Party):
Kaiser Permanente Identifier:
First received: February 26, 2009
Last updated: April 2, 2015
Last verified: March 2015
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.

Condition Intervention
Leprosy Drug: clofazamine

Study Type: Expanded Access     What is Expanded Access?
Official Title: Clofazamine in the Long Term Treatment of Leprosy, Phase III

Resource links provided by NLM:

Further study details as provided by Kaiser Permanente:

Intervention Details:
    Drug: clofazamine
    clofazamine 50mg po qday (duration varies according to physician)
Detailed Description:
Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Known or suspected leprosy confirmed by skin biopsy and/or slit skin smears.
  • Multibacillary leprosy (lepromatous leprosy or borderline-lepromatous).
  • Paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if there is involvement of the cranial nerves or active acute neuritis.
  • Known or suspected ENL(erythema nodosum leprosum) (a specific immune reaction with painful skin nodules and fever)
  • Known or suspected dapsone-resistant leprosy or relapsed leprosy.
  • Intolerance of other antileprosy antibiotic (where clofazamine is substituted as apart of multidrug regimen)

Exclusion Criteria:

  • Uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone and rifampin only.
  • Known prior intolerance of Clofazamine
  • Any minor (even with parental consent)
  • Any fertile woman who is pregnant a specific immune reaction with painful skin rash and fever)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852345

United States, California
Kaiser Permanente
Irvine, California, United States, 92618
Sponsors and Collaborators
Kaiser Permanente
Health Resources and Services Administration (HRSA)
Principal Investigator: Arnold M Henson, MD Kaiser Permanente
  More Information

Responsible Party: Kaiser Permanente Identifier: NCT00852345     History of Changes
Other Study ID Numbers: IRB 5347
KPSC IRB 5347 ( Other Identifier: Kaiser Permanente )
Study First Received: February 26, 2009
Last Updated: April 2, 2015

Keywords provided by Kaiser Permanente:
multibacillary leprosy

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Inflammatory Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 20, 2017